LRRC52: A Promising Drug Target and Biomarker for Cancer (G440699)

Target Name: LRRC52

NCBI ID: G440699

LRRC52

LRRC52: A Promising Drug Target and Biomarker for Cancer

Cancer is a leading cause of morbidity and mortality worldwide, affecting millions of individuals worldwide. The development of new treatments and biomarkers for cancer has become a major focus in the pharmaceutical industry. One such promising drug target and biomarker is LRRC52, a subunit of the BK channel gene. In this article, we will discuss LRRC52, its potential as a drug target and biomarker, and its research in the context of cancer.

LRRC52: The BK Channel and Cancer

The BK channel is a family of proteins that play a critical role in cell signaling. The BK channels are involved in the regulation of cell proliferation, differentiation, and survival. LRRC52 is a subunit of the BK channel gene that has been identified as a potential drug target and biomarker for cancer.

Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. This growth is caused by a variety of factors, including genetic mutations, inflammation, and signaling disruptions. The BK channels are involved in the regulation of cell growth and proliferation, making them an attractive target for cancer treatments.

LRRC52: A Unique BK Channel Subunit

LRRC52 is a unique BK channel subunit due to its unique structure and function. It has a single open reading frame and is composed of 185 amino acid residues. LRRC52 is expressed in a variety of tissues, including brain, heart, skeletal muscles, and various organs.

LRRC52 functions as a negative regulator of the BK channel. It binds to the BK channel and prevents it from activating. This inhibition of BK channel activity can lead to the inhibition of cell proliferation and the regulation of cell survival.

LRRC52 has been shown to be a potential drug target for cancer. Studies have shown that LRRC52 can inhibit the growth of cancer cells in a variety of models, including breast, ovarian, and colorectal cancer. Additionally, LRRC52 has been shown to be downregulated in various types of cancer, which suggests that it may be an attractive target for cancer treatments.

LRRC52: A Potential Biomarker

LRRC52 has also been shown to be a potential biomarker for cancer. The downregulation of LRRC52 has been observed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that LRRC52 may be a useful biomarker for cancer diagnosis and monitoring.

LRRC52 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that LRRC52 is downregulated in various types of cancer. These findings suggest that LRRC52 may be a useful biomarker for cancer diagnosis and monitoring.

The Potential for LRRC52 as a Drug Target

LRRC52 has been shown to be a potential drug target for cancer. Its inhibition of BK channel activity and its potential as a biomarker make it an attractive target for small molecule inhibitors.

Various studies have shown that LRRC52 can be inhibited by small molecules, including inhibitors of the BK channel. These inhibitors have been shown to inhibit the growth of cancer cells in a variety of models.

The potential benefits of LRRC52 as a drug target are significant. It has the potential to be used in a variety of cancer types, including breast, ovarian, and colorectal cancer. Additionally, its use as a biomarker could potentially improve cancer diagnosis and monitoring.

Conclusion

LRRC52 is a unique BK channel subunit that has been identified as a potential drug target and biomarker for cancer. Its inhibition of BK channel activity and potential as a biomarker make it an attractive target for small molecule inhibitors. Further research is needed to

Protein Name: Leucine Rich Repeat Containing 52

Functions: Auxiliary protein of the large-conductance, voltage and calcium-activated potassium channel (BK alpha). Modulates gating properties by producing a marked shift in the BK channel's voltage dependence of activation in the hyperpolarizing direction, and in the absence of calcium. KCNU1 channel auxiliary protein. May modulate KCNU1 gating properties

The "LRRC52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets